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Abstract
Background: Hepatitis B coinfection is common in HIV-positive individuals and as antiretroviral therapy has made death due
to AIDS less common, hepatitis has become increasingly important. Several drugs are available to treat hepatitis B. The most
potent and the one with the lowest risk of resistance appears to be tenofovir (TDF). However there are several questions
that remain unanswered regarding the use of TDF, including the proportion of patients that achieves suppression of HBV
viral load and over what time, whether suppression is durable and whether prior treatment with other HBV-active drugs
such as lamivudine, compromises the efficacy of TDF due to possible selection of resistant HBV strains.
Methods: A systematic review and meta-analysis following PRISMA guidelines and using multilevel mixed effects logistic
regression, stratified by prior and/or concomitant use of lamivudine and/or emtricitabine.
Results: Data was available from 23 studies including 550 HBV/HIV coinfected patients treated with TDF. Follow up was for
up to seven years but to ensure sufficient power the data analyses were limited to three years. The overall proportion
achieving suppression of HBV replication was 57.4%, 79.0% and 85.6% at one, two and three years, respectively. No effect of
prior or concomitant 3TC/FTC was shown. Virological rebound on TDF treatment was rare.
Interpretation: TDF suppresses HBV to undetectable levels in the majority of HBV/HIV coinfected patients with the
proportion fully suppressed continuing to increase during continuous treatment. Prior treatment with 3TC/FTC does not
compromise efficacy of TDF treatment. The use of combination treatment with 3TC/FTC offers no significant benefit over
TDF alone.
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Introduction
Approximately 10% of people infected with HIV are coinfected
with hepatitis B virus (HBV). Among populations with access to
antiretroviral therapy (ART), in whom serious opportunistic
infections have become a rare event, liver diseases including
HBV infection represent a major cause of morbidity and mortality.
[1] Since the life-cycles of HIV and HBV both utilise a reverse
transcriptase enzyme, some drugs that inhibit reverse transcriptase
have activity against both viruses. Guidelines now recommend
tenofovir (TDF) in combination with lamivudine (3TC) or
emtricitabine (FTC) as first-line therapy for patients with HIV/
HBV coinfection. [2] Many studies have reported on the effect of
TDF, either with or without 3TC or FTC, in treatment-naı¨ve or
experienced patients, however many studies are small and with
relatively short follow-up.
It is uncertain what proportion of patients achieves suppression
of HBV DNA (viral load) and whether those in whom suppression
is not seen after one year may achieve HBV suppression later. It is
also unclear to what extent, if at all, those with complete
suppression may relapse despite continued treatment, e.g. in case
of development of resistance mutations. Finally, it remains
uncertain whether sequential treatment, for example with 3TC
initially and TDF later, compromises the chance of successful
treatment with TDF.
A recent meta-analysis examined all randomised controlled
trials of treatment for HBV but excluded patients with HIV
coinfection and only compared responses at 12 months. [3]
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Outcomes included both virological (undetectable HBV viral load
– excluded if the lower limit of detection was greater than 1000
copies/mL) and biochemical responses, HBeAg loss or serocon-
version to anti-HBe, HBsAg loss, histological improvement and
serious adverse events.
We carried out this meta-analysis of data from patients
coinfected with HIV to amalgamate all available evidence and
to answer the following questions:
(i) what proportion of patients achieve HBV viral load
suppression on TDF?
(ii) does the rate of suppression differ in those with prior 3TC
experience?
(iii) does the rate of suppression differ in those treated with
combination therapy compared with TDF monotherapy?
(iv) how common is HBV rebound on TDF?
Methods
The systematic review was carried out following the guidance
laid out in the PRISMA statement [4].
Search Strategy and Selection Criteria
Studies included were those that described HBV/HIV coin-
fected individuals treated with TDF with or without 3TC and/or
FTC for a period of at least one year and that gave results of
quantification of plasma HBV viral load at yearly intervals (at a
minimum) while on TDF treatment. Studies included could be
randomised controlled trials or prospective or retrospective cohort
studies. Patients with undetectable plasma HBV viral load at
Figure 1. Summary of study search and inclusion (PRISMA flow diagram).
doi:10.1371/journal.pone.0068152.g001
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baseline were excluded since their inclusion gives a falsely high
estimate of the effect of treatment. Baseline HBV viral load data
was not given for 20 patients in three studies (see Table 1). The
analysis was restricted to patients on TDF treatment, with or
without 3TC and/or FTC. In this analysis inclusion bias could be
considerable if patients who failed to suppress either stopped
taking TDF or had progressive liver disease and so dropped out.
This would leave a higher proportion of patients with a good
response, overestimating the treatment effect. However very little
data required to deal with this has been published. Further analysis
of individual patient data was carried out where this was available
or was provided in the process of performing the current analysis
(Table 1).
TDF received approval for the treatment of HIV infection from
the United States Food and Drug Administration (FDA) in
October 2001 and from the European Medicines Agency in
February 2002. (FDA approval for the treatment of chronic HBV
infection was granted in August 2008.) The first reports of the use
of TDF in treating HBV infection were presented in 2002. Web of
Science, Embase and Medline were searched, including all years.
Conference abstracts from The Liver Meeting (American Associ-
ation for the Study of Liver Diseases), The International Liver
Congress (European Association for the Study of the Liver) and
the Conference on Retroviruses and Opportunistic Infections were
searched for the years 2002–2010.
To search databases, a combination of key terms was used
including ‘‘hepatitis’’, ‘‘HIV’’, and ‘‘tenofovir’’, limited to articles
with human subjects and written in English (Appendix S1).
Conference abstracts were searched online or by hand. Other
publications that were discovered from the reference lists in
publications reviewed were also included.
Data Collection
Studies were screened initially by title and then data was
collected by HP from the full article of all published studies and
from conference posters, or conference abstracts if posters were
not available. Some studies met the eligibility criteria except that
the published report did not include data on the number with
undetectable HBV viral load at one year, or information on prior
or concomitant drug exposure. The authors of these studies were
contacted by email and asked to provide additional data if
available. Additional, unpublished data was obtained from the
authors of 11 of the 23 sources included (Table 1). The authors of
one conference report provided an article that superseded the
conference report and which had been accepted and published
online but that had not been discovered in the search [13].
Data collected consisted of type of study, source of study
funding, number of HBV/HIV coinfected participants, number
HBeAg positive at study entry, prior 3TC/FTC exposure, drug
regimens used during study period, length of follow-up, type of
HBV viral load test used and lower limit of detection, numbers
tested for HBV viral load at yearly intervals, and numbers with
undetectable HBV viral load at yearly intervals. To maximise
power and in the absence of any evidence suggesting a difference
in effect on HBV between 3TC and FTC, exposure to these two
were grouped together.
Results were stratified by treatment into four groups. Group A
consisted of patients who had no prior exposure to 3TC/FTC and
who were treated with TDF without concomitant 3TC/FTC,
Group B those without prior exposure to 3TC/FTC treated with
TDF in combination with 3TC/FTC, Group C those with prior
exposure to 3TC/FTC but treated with TDF without 3TC/FTC,
and Group D those with prior exposure to 3TC/FTC treated with
TDF in combination with 3TC/FTC.
Statistical Analysis
Statistical analysis was carried out using STATA version 10.1.
The main outcome measure used was the proportion of patients
tested who had a HBV viral load below the limit of detection at
each of any available yearly time intervals. 95% confidence
intervals for these proportions were calculated for each time point
in each study and for the aggregate results.
To detect potential sources of bias, assay cut-off was plotted
against proportion suppressed at one year. Publication bias was
examined using funnel plots, in which asymmetry with a lack of
Figure 2. Forest plots of study arms included in the meta-analysis at years 1–3.
doi:10.1371/journal.pone.0068152.g002
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poorly performing studies (to the left) would suggest such studies
were not published.
Multilevel mixed effects logistic regression (XTMELOGIT
command) was used to assess the effect of prior exposure to, and
Table 2. Results available for meta-analysis.
Year 1 2 3 4 5 6 7
Group Author S/N S/N S/N S/N S/N S/N S/N
A Nelson 3/10
Matthews 9/12
Kosi 8/9 9/11
Tan 0/1 1/1 1/1
B Dore 4/5
Bani-Sadr 5/6 6/6
Stephan 4/6
Nelson 2/6
Schmutz 15/24 15/17 12/13 4/5
Jain 7/9
Matthews 7/10
Nu¨esch 5/5 2/2
Tuma 9/9
Kosi 8/12 11/14
Lee 2/8 2/4 5/6 2/2 1/1
Tan 3/6 4/6 2/4 4/4 3/3
Kuzushita 9/14 12/13 8/8 5/5 5/5
Avihingsanon 9/10
de Vries-Sluijs 12/28 18/24 19/23 14/14 6/6 1/1
Rodriguez 3/6
Engell 6/10 5/5
C van Bommel 11/11
Stephan 1/3
Nelson 4/12
Schmutz 27/48 38/40 30/32 9/9
Lee 1/1
Kosi 1/3 2/3
Tan 0/2 2/2 1/1
D Marcelin 3/10
van Bommel 10/10
Stephan 8/14
Nelson 6/11
Peters 7/18
Jain 10/19 1/2
Gutie´rrez 3/6 2/2 1/1
Quiros-Roldan 7/10 8/9 7/7 5/5 1/1
Tuma 22/29
Lee 2/3 3/3 2/2
Kosi 11/15 13/16
Tan 14/20 12/15 10/14 7/8 7/9
de Vries-Sluijs 14/50 34/49 38/47 33/38 21/23 8/8 1/1
Engell 3/11 4/13
Butt 2/5 3/5 3/5
S: number of HBV viral load test results showing viral suppression (below the level of detection).
N: number of patients with a HBV viral load test performed.
doi:10.1371/journal.pone.0068152.t002
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combination treatment with 3TC/FTC on the probability of viral
suppression, with individual studies fitted as a random effect to
account for clustering (Appendix S2). This implicitly weights each
study by the amount of information it contains. Since there was no
association of assay cut-off with rate of suppression the model was
not adjusted for cut-off. The significance of between study
heterogeneity was assessed by a likelihood-ratio test comparing
the mixed effects model with a standard logistic regression model.
Models were re-run with an interaction term to examine
whether the effect of concomitant 3TC/FTC was the same in both
those naı¨ve and those exposed to prior 3TC/FTC. As sensitivity
analyses, the model was re-run (i) including only larger studies
(reporting at least ten patients), (ii) including all studies apart from
one that appeared as an outlier on the funnel plot. [8] and (iii) with
a term for study design.
All authors had access to the data in the study and reviewed and
approved the manuscript.
Results
The initial searches produced 2,110 references which, after
duplicates were removed, referred to 1,607 publications. Publica-
tions were then screened by title and if necessary by abstract to
remove those clearly not meeting the eligibility criteria. This left
379 published articles. The full text of articles and posters was then
checked for eligibility (or abstracts if the full article or poster was
not available). 356 were removed as ineligible (as described in
Figure 1) and 23 included in the analysis.
Study characteristics are given in Table 1. Although data was
included from six randomised controlled trials, allocation of TDF
vs. TDF plus 3TC was randomised in only two. [17,18] Some
studies included patients in more than one treatment group (for
example both patients with and without prior exposure to 3TC),
giving 43 study arms in total (Table 2 and Figure 2).
In cases where insufficient data was published to categorise
participants for this meta-analysis (for example if it was impossible
to separate according to prior/concomitant treatment or if
individuals with undetectable HBV viral load at baseline were
included [29]), authors were contacted for further information.
Those studies for which published data has been augmented by
additional information are so labelled in Table 1.
Studies used assays with widely varying cut-offs for the detection
of HBV (Table 1). This could have introduced bias, with the use of
more sensitive assays resulting in an apparent lower rate of
suppression. However plotting the proportion undetectable against
the logarithm of the cut-off value showed no clear pattern
(Figure 3) and the cut-off was ignored in further analyses.
The overall proportion suppressed was 57.4% (95% CI: 53.0–
61.7%), 79.0% (95% CI: 73.6–83.8%), and 85.6% (95% CI: 79.2–
90.7%) after one, two, and three years of treatment with TDF
(Table 3).
It was possible to assess rates of virological suppression by
HBeAg status for patients from ten of the included studies.
[6,8,13,14,19,21–23,25,27] For HBeAg positive and negative
patients respectively the proportion fully suppressed was 51.8%,
82.0%, 86.6% and 76.3%, 82.1%, 75.0% at one, two and three
Figure 3. Log of HBV viral load assay cut-off against proportion
undetectable at one year.
doi:10.1371/journal.pone.0068152.g003
Table 3. Suppression at yearly time points.
Number suppressed/number tested (% suppressed)
Group A Group B Group C Group D All
Year S/N % S/N % S/N % S/N % S/N %
1 20/32 62.5 110/174 63.2 44/79 55.7 122/231 52.8 296/516 57.4
2 10/12 83.3 75/91 82.4 42/45 93.3 80/114 70.2 207/262 79.0
3 1/1 100 46/54 85.2 32/34 94.1 58/71 81.7 137/160 85.6
S: number of HBV viral load test results showing viral suppression (below the level of detection).
N: number of patients with a HBV viral load test performed.
doi:10.1371/journal.pone.0068152.t003
Figure 4. Percentage with undetectable HBV viral load over
time, by HBeAg status.
doi:10.1371/journal.pone.0068152.g004
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years (Figure 4). After one year of treatment, a higher proportion
of HBeAg negative than HBeAg positive individuals had a fully
suppressed HBV viral load (p = 0.005). However, after one year
the rates of suppression were not significantly different.
Table 4 shows the effects of prior and concomitant 3TC/FTC
on virological suppression. Effects are given for all patients and
also stratified by prior or concomitant treatment with 3TC/FTC
as appropriate. Overall, at one year prior exposure to 3TC had an
odds ratio of 0.69 (95% CI: 0.45 to 1.08) and treatment with 3TC/
FTC in addition to TDF of 1.24 (95% CI: 0.68 to 2.24), neither
being statistically significant. The effect of prior exposure to 3TC/
FTC was similar, but also not statistically significant, at each of
one, two, and three years. The effect of concomitant treatment
with 3TC/FTC favoured dual therapy at one year but TDF
monotherapy at years two and three, but these effects were again
not statistically significant. The odds ratios in the stratified analyses
were similar to the effects overall but with even wider confidence
intervals. There was no evidence of an interaction between prior
and concomitant 3TC/FTC treatment (p = 0.98 at 1 year,
p = 0.14 at 2 years and p= 0.99 at 3 years). Between-study
heterogeneity, allowing for the effects of prior and concomitant
3TC/FTC treatment, was significant (p,0.01) at year 1 but not at
year 2 (p = 0.48) or at year 3 (p = 1.0).
The proportion suppressed increased over time and reached
100% overall (Table 2). The number of patients in follow-up at
each year declined, however of the 379 patients in studies with
more than one year of follow-up, individual patient data was
available for 187 (49.3%) and in these patients dropping out (i.e.
no later HBV viral load test result being available) was more likely
at every time point for patients with suppressed HBV than for
those with detectable HBV (non-significant – data not shown).
Virological rebound on TDF was rare, with no cases seen in 16
of 23 studies. Three studies reported a single patient with an
increase in HBV viral load on TDF treatment, [17,21,25] three
had two patients, [7,14,22] and one had three [8] though in three
of these studies the size of the increases were not reported, in two
the increases were very small (0.1 to 0.3 log), and only two had
patients with an increase of at least one log (one in each study).
[7,22] Unfortunately no discussion of these two cases was given, in
particular there were no data on drug compliance and treatment
adherence.
The funnel plot (Figure 5) shows the standard error against the
proportion undetectable at one year, with the vertical line marking
the summary estimate of the treatment effect (derived using fixed-
effect meta-analysis). [28] The plot is symmetrical with no
suggestion of publication bias. There is considerable heterogeneity
in the effect found in larger studies (appearing higher up on the
graph with a lower standard error), with one apparent outlier with
a low proportion undetectable despite large size (de Vries-Sluijs,
[8] Group D). Separate funnel plots of each arm in the analysis
also show no publication bias (not shown). Repeating the
regression analysis after excluding the outlier study arm and after
excluding small studies (with less than ten patients) made no
significant difference to the results. The model included a term for
study design and showed that study design had no significant
impact on the results, with p values of 0.76, 0.54 and 0.42 at 1, 2
and 3 years in the overall analysis.
Discussion
This review of HBV/HIV coinfected patients treated with TDF
results demonstrates lasting virological suppression of HBV
replication to below the level of detection, with the proportion
suppressed increasing to 100% over time, though with small
numbers at later time points. Few patients experience virological
failure on treatment.
However several reservations should be noted. Firstly most of
the studies included were observational in design and patients
Table 4. Multivariate logistic regression analysis of effects of prior and concomitant 3TC/FTC on virological suppression.
Effect of prior 3TC/FTC Effect of concomitant 3TC/FTC
Monotherapy Dual therapy Overall 3TC/FTC naive
Prior 3TC/FTC
exposure Overall
Year OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
1 0.37 0.09 to 1.59 0.64 0.39 to 1.06 0.69 0.45 to 1.08 1.13 0.40 to 3.15 2.14 0.75 to 6.12 1.24 0.68 to 2.24
2 0.80 0.06 to 11.50 0.55 0.20 to 1.49 0.69 0.35 to 1.39 0.94 0.19 to 4.70 0.23 0.03 to 1.64 0.37 0.11 to 1.30
3 – – 0.77 0.30 to 2.03 0.75 0.29 to 1.96 – – 0.28 0.06 to 1.96 0.25 0.05 to 1.14
Monotherapy: patients treated with TDF without concomitant 3TC/FTC, i.e. groups A and C.
Dual therapy: patients treated with TDF with concomitant 3TC/FTC, i.e. groups B and D.
3TC/FTC naı¨ve: patients not previously exposed to 3TC/FTC before TDF treatment, i.e. groups A and B.
Prior 3TC/FTC exposure: patients previously exposed to 3TC/FTC before TDF treatment, i.e. groups C and D.
OR: odds ratio.
CI: confidence interval The effects comparing groups A and C and comparing groups A and B in year 3 were non-estimable as there is only one patient in group A.
doi:10.1371/journal.pone.0068152.t004
Figure 5. Funnel plot of standard error against proportion
undetectable at one year – all study arms (with pseudo 95%
confidence limits).
doi:10.1371/journal.pone.0068152.g005
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dropping out were not well characterised. Secondly, in this meta-
analysis we compare different treatment groups though allocation
to these was randomised in only two studies. [17,18] Thirdly the
numbers of patients included in the meta-analysis declines rapidly
over time.
The proportion with undetectable HBV at one year (59%) was
lower than the proportion found in HIV negative patients
receiving TDF for treatment of HBV infection. For example, a
multicentre cohort study found that, of 54 HIV-negative patients
treated with TDF and FTC, 60% of whom were HBeAg positive,
the probability of attaining an undetectable HBV viral load was
76% at one year and 94% at two years. [30] Similarly, in a large
randomised controlled trial comparing TDF with adefovir,
Marcellin found 93% of 250 HBeAg negative and 76% of 176
HBeAg positive patients randomised to TDF had an undetectable
viral load (,400 copies/mL) at 48 weeks (97% and 83%
respectively of those still on TDF at 48 weeks) [31].
In the latter study, ten patients (2.3%) had virological
breakthrough (defined in that study as detectable HBV after an
undetectable result or an increase in HBV viral load by a factor of
ten from nadir). [31] Of the 550 patients in the current study, we
identified 12 (2.4%) with a rise in HBV viral load on TDF
treatment (although at least five of these 12 had less than a one log
rise from nadir) which is comparable to HBV-monoinfected
patients. However other published data in coinfected patients have
found far higher rates, for example 9 (17%) of 52 patients followed
up for a median of 34 months in one retrospective cohort study
(which was not included in the current meta-analysis as data on
HBV viral load suppression was only given at the end of follow-up
and not at yearly time points) [32].
The high rate of virological suppression and low rate of
breakthrough may be related to the low chance of developing
TDF-resistance mutations. In HBV/HIV coinfected patients
treated with lamivudine as the only drug active against HBV,
resistance develops in about 90% after four years [33] whereas
mutations associated with TDF resistance, such as the combina-
tion of rtL180M, rtM204V/I and rtA194T [34] or N236T with
A181V, [35] have only rarely been seen and are of uncertain
significance [36–38].
No statistically significant effect of prior 3TC/FTC exposure or
of concomitant 3TC/FTC use was found and thus no evidence to
support the hypotheses that prior exposure may make subsequent
treatment less effective or that concomitant use of 3TC/FTC may
give a higher rate of suppression. However given the modest
number of patients available for inclusion in the meta-analysis, the
confidence intervals were wide and we could not exclude the
possibility of moderately strong effects in either direction. In HIV-
negative patients TDF monotherapy is as effective for HBV as
combination therapy with TDF and 3TC/FTC with suppression
rates (,400 copies/mL) of 81% at one year in both arms of an
RCT using TDF alone or TDF/FTC combination therapy, and
88% and 85% respectively at three years [39,40].
The main concern with sequential treatments that fail to fully
suppress the viral load is that resistance may develop and that
cross-resistance could reduce the efficacy of subsequent drugs.
TDF resistance is yet to be clearly demonstrated but it may be that
the risk of cross-resistance is higher with drugs that are more
similar to TDF in structure than 3TC/FTC. However HBV
mono-infected patients failing to achieve virologic suppression
with adefovir have also been shown to respond well to TDF [41–
43].
A second mechanism by which prior treatment exposure could
reduce the apparent effectiveness of subsequent TDF is through
introducing bias, in that patients failing one regimen for reasons
other than lack of potency (such as poor adherence to therapy)
may go on to fail other regimens but again, no such reduction in
the effect of TDF in those with prior exposure to 3TC/FTC was
found and so the effect of any such bias must be small.
As stated above, TDF received FDA approval in late 2001 and
thus clinical experience to date is limited to just over one decade.
Although this review includes data to a maximum of seven years, a
lack of data limited the main regression analyses to three years.
Patients with HIV require lifelong treatment and patients with
HBV coinfection are likely to require the same. The possibility of
safe discontinuation of HBV treatment may be limited to patients
who clear serum hepatitis B surface antigen (HBsAg). However the
probability of HBsAg loss is low with a rate of approximately 2.5%
per year [44,45] with the predicted median time to HBsAg
seroclearance in HBeAg positive patients treated with TDF being
18 years (IQR 10–28 years) [46].
A limitation of this study is that it does not include analysis of
the adverse effects of treatment. Future studies with longer follow-
up duration will be required to determine the risk of treatment
associated adverse effects, such as renal and bone toxicity, in
patients exposed to TDF for many decades.
In conclusion, this meta-analysis shows that tenofovir suppresses
HBV to undetectable levels in the majority of HBV/HIV
coinfected patients, with the proportion fully suppressed increasing
with time on treatment and with little if any virological rebound on
treatment. Prior treatment with 3TC/FTC does not alter the
efficacy of TDF treatment. Combination treatment with 3TC/
FTC offers no significant benefit over tenofovir alone.
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